Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile SRC positive
Therapy BIRB-796 + Dasatinib
Indication/Tumor Type triple-receptor negative breast cancer
Response Type sensitive


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
SRC positive triple-receptor negative breast cancer sensitive BIRB-796 + Dasatinib Preclinical - Cell culture Actionable In a preclinical study, BIRB-796 in combination with Sprycel (dasatinib) resulted in improved growth inhibition in both 2D and 3D cultures of triple-receptor negative breast cancer cell lines with elevated Src activity compared to single agent treatment (PMID: 27154914). 27154914
PubMed Id Reference Title Details
(27154914) UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer. Full reference...